BPK Bespak

RNS Number:0151W
Bespak PLC
03 May 2007


                                   Bespak plc
                                        
                Strong trading in the 52 weeks to 28 April 2007
                                        
                                        
Bespak plc (LSE:BPK), a leader in devices for inhaled drug delivery and
anaesthesia, anticipates that reported performance in the year ending 28 April
2007 will be in line with or will marginally exceed expectations with strong
trading in both its Inhaled Drug Delivery and Anaesthesia & Respiratory Care
business segments.

Inhaled Drug Delivery continued the strong organic growth reflected in the first
half with record sales of CFC-free valves and dry powder inhalers. The
transition in the US market to CFC-free asthma formulations progresses more
successfully than anticipated. Bespak has also won a number of new valve and
dose counter development programmes during the year. Bespak has continued to
benefit from demand for the Exubera(R) inhaler to support its global launch,
although there are uncertainties about short- to medium- term sales volumes.

The good performance in Anaesthesia & Respiratory Care reflected the first full
year of the King Systems acquisition, and reflected the same growth trajectory
seen in the first half. King Systems is a leading supplier of disposable
breathing circuits, masks and laryngeal tubes, mainly sold to hospitals in the
US.

Last month Bespak announced the two-step acquisition of Emergent Respiratory
Products of Irvine, California. This acquisition is highly complementary to King
and will expand Bespak's access to the growing pre-hospital emergency medicine
market segment where Bespak's existing airway management products have
considerable potential.

Bespak will report its preliminary results on 11 July 2007.
 

For further information please contact:

Bespak
Mark Throdahl, Chief Executive               Tel: +44 (0)1908 552600
Jonathan Glenn, Group Finance Director


Maitland
Brian Hudspith or Liz Morley                 Tel: +44 (0)20 7379 5151


Bespak plc is a leader in specialty medical devices, developing delivery systems
for the pharmaceutical industry and disposable airway management products for
critical care settings.

The company develops and manufactures metered dose inhalers, actuators,
compliance aids, dry powder devices, disposable facemasks, breathing circuits,
and laryngeal tubes. The group holds the 2005 Frost & Sullivan Award for
Technology Innovation and has facilities in King's Lynn and Milton Keynes in the
UK, in Indianapolis, Indiana and Kent, Ohio, in the US, and in Mumbai, India.
Bespak is a public company quoted on the full list of the London Stock Exchange
(LSE: BPK).

 




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
TSTFGGGKRZKGNZM

Bespak (LSE:BPK)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Bespak (LSE:BPK)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024